



PRESS RELEASE

10 February 2021

## Recipharm bolsters biologics offering

Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers' vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms.

The license, which applies to its facility in Wasserburg, Germany, also covers microbiological testing allowing Recipharm to insource bacterial endotoxin testing on its products, including testing diluent for one of the COVID-19 vaccines.

Kjell Johansson, President Manufacturing Services Europe said: "Vaccine manufacturing capacity and the associated testing is more crucial than ever, so we're delighted to be able to further support our customers in the area."

"The Recipharm team has extensive experience in handling products with aseptic requirements and this accreditation is just the latest step in ultimately bolstering our biologics offering for customers. This will allow us to not only to cater for requirements for the current pandemic, but also future requirements as we continue to see more biologics enter the drug pipeline."

The new accreditation includes key biologic analytical techniques, including gel electrophoresis, UV/VIS spectrophotometers and osmometers, with plans to add more in 2021. In addition, the facility has also bolstered its packaging capabilities to support customers with clinical trial packaging.

### Contact information

Kjell Johansson, President Manufacturing Services Europe, [kjell.johansson@recipharm.com](mailto:kjell.johansson@recipharm.com), +46 8 6024 670  
Michael Isele, General Manager, [michael.isele@recipharm.com](mailto:michael.isele@recipharm.com), +49 8071 1008 111

For media enquiries, please contact Kate Hindhaugh at [ramarketing](mailto:ramarketing@ramarketingpr.com): [kate@ramarketingpr.com](mailto:kate@ramarketingpr.com), +44 (0)191 222 1242, [ramarketingpr.com](http://ramarketingpr.com), Twitter: [@ramarketingpr](https://twitter.com/ramarketingpr), Facebook: [/ramarketingpr](https://facebook.com/ramarketingpr), LinkedIn: [/ramarketing](https://linkedin.com/company/ramarketingpr)

### About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit [www.recipharm.com](http://www.recipharm.com)